{
    "nctId": "NCT00291694",
    "briefTitle": "Protocol for Women at Increased Risk of Developing Breast Cancer",
    "officialTitle": "A Double-blinded Phase II Study of the Expression of Ki-67/MIB-1 in Women With Hyperplasia of the Breast Randomized to Receive Daily Celecoxib 400 mg BID or Placebo",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 72,
    "primaryOutcomeMeasure": "Change in Percent of Breast Epithelial Cells Staining Positive for Ki-67",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* women who have a high risk of breast cancer\n* older than 18 years\n\nExclusion Criteria:\n\n* anticoagulants\n* marked breast tenderness\n* pregnant or within twelve months of breast feeding/childbirth",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}